In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

VaxInnate's $30mm Series D supports swine flu vaccine candidate

Executive Summary

Vaccines developer VaxInnate completed a $30mm Series D financing to lead and first-time backer Wellcome Trust, which adds a board member. Returning shareholders CHL Medical Partners, Canaan Partners, HealthCare Ventures, MedImmune Ventures, New Leaf Venture Partners, and Oxford Bioscience Partners also participated. The money will support clinical trials of various infectious disease vaccines, as well as the continued development of a prototype swine flu vaccine, which should enter preclinical studies in about a month. It is possible that at the government's request, VaxInnate could begin manufacturing a swine flu vaccine within weeks of the product's approval to meet the needs of the current global crisis. To date the company has raised about $95mm in venture funding.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies